Long Term Follow up in Sickle Cell Patients Treated by Hydroxyurea

HaEmek Medical Center, Israel

Status: Completed

Conditions: Sickle Cell Thalassemia; Sickle Cell Anemia

Treatments: Other: Clinical follow up and laboratory analysis

Study type: Observational

Funder types: Other

Identifiers

NCT00480974

5321006.EMC

Details and patient eligibility

About

Hydroxyurea was found to be a good treatment in adult patients with sickle cell anemia with significant decrease in the frequency of vaso-occlusive crises and other crises related to SCA. Several studies were published with relative short term follow up in pediatric and young adult age. The purpose of this study is to assess the long term follow up in a group of patients that initiated Hydroxyurea treatment in childhood.

Full description

Hydroxyurea was found to be a good treatment in adult patients with sickle cell anemia with significant decrease in the frequency of vaso-occlusive crises and other crises related to SCA. Several studies were published with relative short term follow up in pediatric and young adult age. The purpose of this study is to assess the long term follow up in a group of patients that initiated Hydroxyurea treatment in childhood.

A long term follow up will be recorded in a cohort of twenty SCA patients treated by Hydroxyurea for a period between 5 to 12 years. The frequency of vaso-occlusive crises, acute chest syndrome, blood transfusions, and hospitalization will be recorded retrospectively. Also the mean hgb level and hgb F percentage will be summarized.

Enrollment: 20 estimated patients

Sex: All

Ages: 5 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• All patients treated by Hydroxyurea in the Pediatric Hematology Unit.

Trial design

20 participants in 1 patient group

1

Description:

Patients with Sickle cell anemia treated by Hydroxyurea

Treatment:

Other: Clinical follow up and laboratory analysis